Ou Guo-Chun, Luo Wen, Zhang Wei-Shan, Wang Shu-Hong, Zhao Jie, Zhao Hong-Mei, Qiu Rong
Department of Respiratory and Critical Care Medicine, Suining Central Hospital, Suining 629000, Sichuan Province, China.
Department of Pathology, Suining Central Hospital, Suining 629000, Sichuan Province, China.
World J Clin Cases. 2023 Jan 16;11(2):441-448. doi: 10.12998/wjcc.v11.i2.441.
Lung invasive mucinous adenocarcinoma (LIMA), formerly referred to as mucinous bronchioloalveolar carcinoma, is a rare disease that usually presents as bilateral lung infiltration, is unsuitable for surgery and radiotherapy, and shows poor response to conventional chemotherapy.
We report a 56-year-old Chinese man with a history of smoking and epidermal growth factor receptor mutation-positivity who was initially misdiagnosed as severe pneumonia, but was ultimately diagnosed as a case of invasive mucinous adenocarcinoma of the lung by computed tomography -guided percutaneous lung biopsy. Bronchorrhea and dyspnea were improved within 24 h after initiation of gefitinib therapy and the radiographic signs of bilateral lung consolidation showed visible improvement within 30 d. After more than 11 months of treatment, there is no evidence of recurrence or severe adverse events.
Although the precise mechanism of the antitumor effects of gefitinib are not clear, our experience indicates an important role of the drug in LIMA and provides a reference for the diagnosis and treatment of this disease.
肺浸润性黏液腺癌（LIMA），以前称为黏液性细支气管肺泡癌，是一种罕见疾病，通常表现为双侧肺浸润，不适用于手术和放疗，且对传统化疗反应不佳。
我们报告一名56岁有吸烟史且表皮生长因子受体突变阳性的中国男性，最初被误诊为重症肺炎，但最终通过计算机断层扫描引导下经皮肺活检确诊为肺浸润性黏液腺癌。吉非替尼治疗开始后24小时内，支气管溢液和呼吸困难得到改善，30天内双侧肺实变的影像学征象明显改善。经过11个多月的治疗，没有复发或严重不良事件的证据。
虽然吉非替尼抗肿瘤作用的确切机制尚不清楚，但我们的经验表明该药物在LIMA中具有重要作用，并为该病的诊断和治疗提供了参考。
